2023-505671-74-00已完成4 期
Control Of BioEquivalence with Xenical (COBEX): A Phase I, randomized, active-control study to evaluate EMP22 pharmacodynamics and EMP16 pharmacokinetics versus Xenical® in healthy volunteers.
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Ulf Holmbäck
Scientific
Empros Pharma AB
研究点 (1)
Loading locations...
相似试验
招募中
Unknown
Bioequivalence study of celecoxib 200 mg capsule---.IRCT20230222057495N13Mehr Darou Pharmaceutical Company24
未知
1 期
DMB-3111 phase IHealthy volunteersJPRN-jRCT2080222436Meiji Seika Pharma Co., Ltd.70
尚未招募
不适用
Bioequivalence study of Celecoxib 400 mg in Healthy Thai volunteers under fed conditioBioequivalence generic of celecoxibTCTR20170807001All Research Co., Ltd.46
已完成
不适用
Bioequivalence (BE) Study of a New Branded Generic of Moxifloxacin TabletsMoxifloxacin could potentially cause nausea,diarrhea,headache,vomiting,dizziness,nervousness,agitation and nightmares. As for the safety of the formulation,no adverse event was reported based oMoxifloxacinbioequivalencepharmacokineticsTCTR20201109001/A30
尚未招募
4 期
Bioequivalence Study of 200 mg Celecoxib Capsules in Healthy VolunteersHealthy volunteersTCTR20170612004Pharmacy Service Center42